Maria Rosaria Galdiero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6265335/publications.pdf

Version: 2024-02-01

72 papers 7,050 citations

36 h-index 95266 68 g-index

72 all docs 72 docs citations

72 times ranked

12126 citing authors

#	Article	IF	CITATIONS
1	Macrophage plasticity and polarization in tissue repair and remodelling. Journal of Pathology, 2013, 229, 176-185.	4.5	1,868
2	Tumor associated macrophages and neutrophils in cancer. Immunobiology, 2013, 218, 1402-1410.	1.9	500
3	Tumor associated macrophages and neutrophils in tumor progression. Journal of Cellular Physiology, 2013, 228, 1404-1412.	4.1	346
4	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. Cell, 2015, 160, 700-714.	28.9	334
5	Are Mast Cells MASTers in Cancer?. Frontiers in Immunology, 2017, 8, 424.	4.8	243
6	Neutrophils in innate and adaptive immunity. Seminars in Immunopathology, 2013, 35, 377-394.	6.1	221
7	Mast cells have a protumorigenic role in human thyroid cancer. Oncogene, 2010, 29, 6203-6215.	5.9	190
8	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	4.5	186
9	Eosinophils: The unsung heroes in cancer?. Oncolmmunology, 2018, 7, e1393134.	4.6	184
10	Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors. Cell, 2019, 178, 346-360.e24.	28.9	176
11	Cancer Inflammation and Cytokines. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028662.	5.5	175
12	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	5.1	141
13	Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. International Journal of Molecular Sciences, 2019, 20, 4413.	4.1	140
14	VEGF-A in Cardiomyocytes and Heart Diseases. International Journal of Molecular Sciences, 2020, 21, 5294.	4.1	121
15	Roles of neutrophils in cancer growth and progression. Journal of Leukocyte Biology, 2018, 103, 457-464.	3.3	113
16	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	2.4	99
17	Innate effector cells in angiogenesis and lymphangiogenesis. Current Opinion in Immunology, 2018, 53, 152-160.	5.5	92
18	The immune network in thyroid cancer. Oncolmmunology, 2016, 5, e1168556.	4.6	88

#	Article	IF	Citations
19	Bidirectional Mast Cell–Eosinophil Interactions in Inflammatory Disorders and Cancer. Frontiers in Medicine, 2017, 4, 103.	2.6	88
20	Role of the RNA-Binding Protein Tristetraprolin in Glucocorticoid-Mediated Gene Regulation. Journal of Immunology, 2008, 180, 8342-8353.	0.8	86
21	Cardiac Toxicity of Immune Checkpoint Inhibitors. Circulation, 2017, 136, 1989-1992.	1.6	83
22	Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Advances in Cancer Research, 2015, 128, 141-171.	5.0	81
23	Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019. International Archives of Allergy and Immunology, 2019, 179, 247-261.	2.1	75
24	Neutrophil extracellular traps in cancer. Seminars in Cancer Biology, 2022, 79, 91-104.	9.6	75
25	The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. Frontiers in Immunology, 2018, 9, 2601.	4.8	74
26	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
27	Controversial role of mast cells in skin cancers. Experimental Dermatology, 2017, 26, 11-17.	2.9	69
28	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. International Journal of Molecular Sciences, 2019, 20, 3934.	4.1	69
29	Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils. Frontiers in Immunology, 2017, 8, 443.	4.8	65
30	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Seminars in Cancer Biology, 2022, 79, 180-196.	9.6	64
31	New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101370.	4.7	60
32	Potential involvement of neutrophils in human thyroid cancer. PLoS ONE, 2018, 13, e0199740.	2.5	54
33	Prostaglandin D ₂ receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. Expert Opinion on Investigational Drugs, 2019, 28, 73-84.	4.1	50
34	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1765-1767.	2.8	49
35	Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. International Journal of Molecular Sciences, 2019, 20, 834.	4.1	48
36	Anaplastic Thyroid Cancer Cells Induce the Release of Mitochondrial Extracellular DNA Traps by Viable Neutrophils. Journal of Immunology, 2020, 204, 1362-1372.	0.8	45

#	Article	IF	Citations
37	Neutrophil Extracellular Traps, Angiogenesis and Cancer. Biomedicines, 2022, 10, 431.	3.2	39
38	GM-CSF and IL-3 Modulate Human Monocyte TNF- \hat{l}_{\pm} Production and Renewal in In Vitro Models of Trained Immunity. Frontiers in Immunology, 2017, 7, 680.	4.8	38
39	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	4.0	38
40	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmunity Reviews, 2020, 19, 102590.	5.8	37
41	Human Cardiac Mast Cells in Anaphylaxis. Chemical Immunology and Allergy, 2010, 95, 98-109.	1.7	36
42	Immunosuppressive therapy with rituximab in common variable immunodeficiency. Clinical and Molecular Allergy, 2019, 17, 9.	1.8	36
43	Angiogenesis, Lymphangiogenesis and Atopic Dermatitis. Chemical Immunology and Allergy, 2012, 96, 50-60.	1.7	33
44	IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors. Cells, 2021, 10, 145.	4.1	33
45	The Interplay between the Immune and the Endocannabinoid Systems in Cancer. Cells, 2021, 10, 1282.	4.1	31
46	Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma. Clinical and Experimental Medicine, 2022, 22, 285-300.	3.6	28
47	Lipopolysaccharide-Elicited TSLPR Expression Enriches a Functionally Discrete Subset of Human CD14+CD1c+ Monocytes. Journal of Immunology, 2017, 198, 3426-3435.	0.8	26
48	LPS-mediated neutrophil VEGF-A release is modulated by cannabinoid receptor activation. Journal of Leukocyte Biology, 2021, 109, 621-631.	3.3	25
49	Are Basophils and Mast Cells Masters in HIV Infection?. International Archives of Allergy and Immunology, 2016, 171, 158-165.	2.1	24
50	Mast Cells in Early Rheumatoid Arthritis. International Journal of Molecular Sciences, 2019, 20, 2040.	4.1	24
51	Human Lung-Resident Macrophages Express and Are Targets of Thymic Stromal Lymphopoietin in the Tumor Microenvironment. Cells, 2021, 10, 2012.	4.1	22
52	Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency. Frontiers in Immunology, 2018, 9, 1721.	4.8	19
53	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. Lancet Oncology, The, 2018, 19, 1545-1546.	10.7	16
54	Macrophage-polarizing stimuli differentially modulate the inflammatory profile induced by the secreted phospholipase A2 group IA in human lung macrophages. Cytokine, 2021, 138, 155378.	3.2	13

#	Article	IF	Citations
55	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Seminars in Cancer Biology, 2022, 79, 203-216.	9.6	12
56	Vascular endothelial growth factors and angiopoietins as new players in mastocytosis. Clinical and Experimental Medicine, 2021, 21, 415-427.	3.6	12
57	Roles of Immune Cells in Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 60, 369-382.	6.5	9
58	Impact of a cardioâ€oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Failure, 2022, 9, 1666-1676.	3.1	9
59	Size-based effects of anthropogenic ultrafine particles on activation of human lung macrophages. Environment International, 2022, 166, 107395.	10.0	9
60	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	8
61	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	8
62	Orofacial granulomatosis: Clinical and therapeutic features in an Italian cohort and review of the literature. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2189-2200.	5.7	8
63	Hereditary angioedema attack: what happens to vasoactive mediators?. International Immunopharmacology, 2020, 78, 106079.	3.8	7
64	Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence. Expert Review of Molecular Diagnostics, 2014, 14, 387-399.	3.1	6
65	Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. European Heart Journal, 2022, 43, 330-332.	2.2	6
66	Gender dimorphism in IgA subclasses in T2-high asthma. Clinical and Experimental Medicine, 2023, 23, 929-941.	3.6	5
67	Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. Expert Opinion on Investigational Drugs, 2021, 30, 913-921.	4.1	3
68	Polarized Activation of Macrophages. , 2014, , 37-57.		3
69	First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma. Journal of Clinical Rheumatology, 2020, Publish Ahead of Print, .	0.9	2
70	Tumor-associated Macrophages in Cancer Growth and Progression. , 2013, , 451-471.		1
71	Neutrophils Involvement in Human Thyroid Cancer. Journal of Allergy and Clinical Immunology, 2018, 141, AB122.	2.9	O
72	Abstract SY06-01: Tumor-associated myelomonocytic cells as therapeutic targets. , 2017, , .		0